QRISK3 (OSCE focused) ❤️

🧮 QRISK3 estimates a person’s 10-year risk of developing a first cardiovascular event (e.g., MI or stroke) using UK population data. It is mainly used in primary prevention to guide shared decisions about lifestyle and lipid-lowering therapy (especially statins).

🎯 What QRISK3 is for (and why it matters)

• ✅ Quantifies baseline risk to support shared decision-making rather than “treating a number”.
• 🧠 Helps clinicians explain absolute risk (e.g., “10% over 10 years”) and the potential benefits of interventions.
• 💊 Underpins UK primary prevention statin decisions (see NICE guidance below).
• 🧭 Flags when risk may be underestimated (e.g., strong family history, complex multimorbidity) so you can safety-net and individualise.

👥 Who it applies to

• 📌 Designed for people aged roughly 25–84 years in UK primary prevention.
• 🚫 Not intended for people with established cardiovascular disease (that’s secondary prevention - treat as high risk regardless).
• 🩺 Use clinical judgement if a person’s situation sits outside the model (e.g., unusual conditions or extreme physiology).

🧾 What goes into QRISK3 (high-yield exam list)

QRISK3 combines traditional risk factors with additional clinical variables that can materially change risk estimation. This is one reason QRISK3 can outperform older “basic” calculators in UK practice.

• 🎂 Demographics: age, sex, ethnicity, socioeconomic deprivation (postcode-linked index).
• 🩸 Vitals/labs: systolic BP, cholesterol/HDL ratio, BMI.
• 🚬 Lifestyle: smoking status.
• 🧬 Family history: coronary heart disease in a first-degree relative <60.
• 🩺 Comorbidities: diabetes, CKD, AF, rheumatoid arthritis, SLE, severe mental illness, migraine, treated hypertension.
• 💊 Medicines/clinical states that shift risk: corticosteroids, atypical antipsychotics, erectile dysfunction, HIV, and others (model-dependent).

🧠 The “why” (teaching points for medical students)

Atherosclerotic cardiovascular disease is driven by endothelial injury and lipid deposition, amplified by inflammation, thrombosis risk, and long-term haemodynamic stress. QRISK3 tries to capture this biology indirectly: for example, chronic inflammatory disease (RA/SLE) increases cytokine-driven vascular injury; CKD accelerates vascular calcification and dyslipidaemia; and AF increases embolic stroke risk. The key clinical skill is translating a probabilistic risk score into a personalised plan the patient understands and can act on.

📌 How to interpret the result (OSCE phrasing)

• 🔢 “Your QRISK3 score is X%, meaning about X in 100 people like you may have a heart attack or stroke in the next 10 years.”
• 🧩 Combine with the whole picture: symptoms, frailty, patient priorities, comorbidities, and whether risk might be underestimated.
• 📉 Emphasise modifiable drivers: smoking, BP control, weight, activity, diabetes control, and lipid lowering.

💊 What QRISK3 usually triggers in UK practice (NICE-aligned)

• 🥗 Everyone: lifestyle support (diet, exercise, weight, smoking cessation) and treat reversible secondary causes of dyslipidaemia.
• 💊 Statins for primary prevention: NICE recommends offering atorvastatin 20 mg when the 10-year QRISK3 risk is ≥10%, alongside lifestyle advice.
• 🗣️ Below 10%: NICE advises you should not automatically rule out statins if the person prefers treatment or if risk may be underestimated - this is where shared decision-making matters.

⚠️ Limitations & common pitfalls (examiner favourites)

• 📊 It’s a model, not fate: risk estimates are approximate and depend on data quality (BP, lipids, smoking status).
• 🧾 Bad inputs = bad outputs: single casual BP, missing HDL, or outdated smoking status can mislead.
• 🧓 Older adults: absolute risk rises sharply with age; discuss competing risks, frailty, polypharmacy, and patient goals.
• 🧬 Underestimation: strong family history, certain ethnic groups, chronic inflammation, or multimorbidity can push true risk above the printed score.
• 🩺 Secondary prevention: established CVD generally means high-intensity risk reduction regardless of QRISK3.

🗣️ 60-second OSCE mini-script

• 👋 “I’d like to estimate your 10-year cardiovascular risk using QRISK3 to guide prevention.”
• 🧾 “I’ll confirm your smoking status, BP, cholesterol/HDL, diabetes, kidney disease, and family history, plus conditions/medications that affect risk.”
• 🔢 “Your score is X%. That means about X in 100 people like you may have a heart attack or stroke in the next 10 years.”
• 🎯 “We can lower this risk by addressing lifestyle and treating BP/lipids. If your risk is ≥10%, NICE recommends offering atorvastatin 20 mg, and we decide together based on benefits and preferences.”
• 🧯 “If anything changes - new diabetes, CKD, smoking, or BP - we should recalculate.”

📚 References (UK + core) - MLA style

• National Institute for Health and Care Excellence (NICE). “Cardiovascular Disease: Risk Assessment and Reduction, Including Lipid Modification (NG238) - Recommendations.” NICE, updated 2023. https://www.nice.org.uk/guidance/ng238/chapter/Recommendations.
• QRISK. “QRISK3-2017 Risk Calculator (Online Tool and Supporting Information).” QRISK, accessed 2026. https://www.qrisk.org/.
• Hippisley-Cox, Julia, and Carol Coupland. “Development and Validation of QRISK3 Risk Prediction Algorithms to Estimate Future Risk of Cardiovascular Disease: Prospective Cohort Study.” The BMJ, 2017, doi:10.1136/bmj.j2099.